Beyond Semaglutide: Why Immunogenicity Will Define Success for Generic GLP-1 Agonists and Peptide Therapeutics
The next five years are poised to reshape the global peptide therapeutics market. As patents protecting several blockbuster peptide drugs begin to expire, pharmaceutical companies across the worldincluding Indiaare accelerating the development of generic and follow-on peptide products.
While Semaglutide has become the first major catalyst, it is only the beginning. A new wave of high-value peptide therapeutics is approaching market exclusivity loss, creating unprecedented opportunities for manufacturers prepared to navigate increasingly rigorous regulatory expectations. However, alongside this commercial opportunity comes a critical scientific challenge:
Immunogenicity.
For modern peptide therapeutics, demonstrating pharmacokinetic (PK) comparability alone is no longer enough. Regulatory agencies increasingly expect robust comparative immunogenicity assessments to ensure that generic peptides match the safety, efficacy, and clinical performance of their reference products.
The Generic Peptide Opportunity
Between 2025 and 2030, several commercially important peptide therapeutics are expected to present opportunities for generic or follow-on development in different global markets.
Among the most significant are:
| Molecule | Therapeutic Area | Expected Generic Opportunity * | Estimated Global Market (Peak Sales) | Why Immunogenicity Matters |
|---|---|---|---|---|
| Semaglutide | Type 2 Diabetes, Obesity | Already generic in India (patent expired Mar 20, 2026); core patents expiring in ~10 countries (China, Brazil, Turkey, Canada, South Africa) by end of 2026. US/UK/EU protected until ~2031+ | Combined Ozempic/Wegovy sales of $26bn in 2024, growing ~40% annually | Long-acting modified peptide with potential immunogenicity arising from manufacturing variability, impurities, and formulation differences. |
| Liraglutide | Type 2 Diabetes, Obesity | Already generic in multiple markets (Victoza patent expired ~2023 in US/EU) | ~USD 3–5 Billion (peak, prior to GLP-1 successor cannibalization) | Chronic administration necessitates robust comparative ADA assessment to demonstrate clinical comparability. |
| Tirzepatide | Type 2 Diabetes, Obesity | US: earliest generic entry projected around December 19, 2028 (Mounjaro) / December 20, 2027 (Zepbound); India composition patents run to ~2031–2033, later than originally stated | Mounjaro and Zepbound had combined sales of nearly $16 billion in 2024 | Structurally more complex than first-generation GLP-1 agonists, requiring comprehensive immunogenicity evaluation. |
| Teriparatide | Osteoporosis | Already off-patent US patent expired 2022; a generic version was approved as teriparatide by Apotex on November 16, 2023. Generic opportunities expanding globally. | ~USD 1–2 Billion | Daily administration and peptide complexity make ADA assessment an important component of comparability. |
| Abaloparatide | Osteoporosis | Emerging opportunity as exclusivity expires across regions. US composition patent expiration dates ranging from 2027 to 2028; earliest date for generic entry estimated October 3, 2027; no generic approved yet as of mid-2026 | ~USD 0.5–1 Billion | Structural modifications and long-term treatment support the need for comparative immunogenicity assessment. |
*Patent expiry and commercial launch timelines vary by country, formulation, regulatory exclusivities, and intellectual property landscape.
Although these molecules differ in structure and therapeutic application, they share one important characteristic: their clinical success depends on maintaining immunological comparability with the innovator product.
Why Peptides Are Different
Unlike conventional small-molecule drugs, peptide therapeutics possess structural complexity that makes them more susceptible to subtle manufacturing-related variations.
Differences in peptide synthesis, purification, formulation, storage conditions, or degradation pathways may introduce:
- Sequence variants and truncations
- Oxidative or chemical modifications
- Process-related impurities
- Peptide aggregation
- Formulation-related differences
Even when these changes appear analytically insignificant, they can alter how the immune system recognizes the molecule, potentially triggering Anti-Drug Antibody (ADA) responses that affect pharmacokinetics, efficacy, or patient safety.
Why PK Equivalence Isn't Enough
Traditional generic drug development has relied heavily on demonstrating bioequivalence through PK studies. For peptide therapeutics, however, PK tells only part of the story.
Two products may exhibit nearly identical PK profiles while generating different immune responses because immunogenicity is influenced by factors that PK studies cannot fully capture, including manufacturing processes, impurity profiles, aggregation, excipient composition, and product stability.
Recognizing this, regulators worldwide are placing increasing emphasis on integrated comparability packages that include analytical characterization, PK, safety, efficacy, and immunogenicity.
Companies relying solely on PK equivalence risk regulatory questions, additional study requests, delayed approvals, or costly redevelopment.
What Regulators Want to Know
Comparative immunogenicity studies help answer several critical regulatory questions:
- Does the follow-on peptide induce antibodies at a rate comparable to the reference product?
- Do these antibodies alter drug exposure or clinical efficacy?
- Are neutralizing antibodies generated?
- Are there emerging safety concerns associated with immune responses?
Answering these questions proactively can significantly streamline regulatory review while reducing development risk.
Common Pitfalls in Generic Peptide Immunogenicity Programs
Many peptide development programs encounter avoidable challenges that compromise regulatory readiness.
| Challenge | Potential Impact |
|---|---|
| Late immunogenicity planning | Missed opportunities for optimized clinical study design |
| Insufficient assay sensitivity | Failure to detect low-level ADA responses |
| Drug interference | Circulating drug masks ADA detection without drug-tolerant assay design |
| Inadequate assay validation | Regulatory deficiencies during submission |
| Poor regulatory alignment | Additional agency questions and delayed approvals |
| Compressed timelines | Increased development risk and compromised data quality |
Building an Effective Immunogenicity Strategy
Successful peptide development begins long before clinical sample testing.
An effective immunogenicity program should include:
- Early immunogenicity risk assessment aligned with global regulatory guidance
- Sensitive and validated ADA assay development
- Drug-tolerant assay platforms capable of detecting antibodies in the presence of circulating drug
- Scientifically justified cut-point determination
- Neutralizing antibody (NAb) assessment where appropriate
- Comprehensive clinical sample analysis with robust quality controls
- Regulatory-ready documentation supporting global submissions
Organizations that integrate these elements early are better positioned to accelerate development while minimizing regulatory uncertainty.
The Bigger Picture
The coming decade will witness one of the largest expansions in generic peptide therapeutics, driven by GLP-1 receptor agonists, dual incretin therapies, hormone analogues, and other complex peptide medicines.
As these therapies become more accessible worldwide, ensuring comparable safety and efficacy extends well beyond analytical similarity and PK equivalence. Immunogenicity assessment provides the confidence that follow-on peptide products will perform consistently throughout long-term clinical use.
Companies that incorporate immunogenicity into their development strategy from the outset will be better equipped to meet evolving regulatory expectations, reduce development risk, and achieve faster market entry in an increasingly competitive landscape.
How Accutest Biologics Supports Generic Peptide Development
At Accutest Biologics, we partner with pharmaceutical and biotechnology companies developing generic GLP-1 receptor agonists and other peptide therapeutics by delivering scientifically rigorous, regulatory-aligned immunogenicity solutions.
Our capabilities include:
- ADA assay development and validation
- Drug-tolerant ADA assay platforms
- Neutralizing antibody (NAb) assay development
- High-throughput clinical sample analysis
- Immunogenicity risk assessment
- Regulatory-ready data packages
- Flexible support for accelerated development timelines
As the global generic peptide market continues to expand, early investment in immunogenicity is becoming a strategic differentiator rather than a regulatory formality.
Organizations that integrate robust immunogenicity assessment into their development programs will be better positioned to achieve regulatory success, accelerate approvals, and deliver safe, effective peptide therapeutics to patients worldwide.
Accutest Biologics supports biosimilars, generic peptides’ development programs with regulatory-aligned ADA testing, drug-tolerant assay platforms, and accelerated clinical sample analysis. For companies navigating compressed timelines, early partnership can reduce risk and accelerate market entry.